RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Knight Therapeutics Stock

Knight Therapeutics Market capitalization 2024

Knight Therapeutics Market capitalization

566.35 M CAD

Ticker

GUD.TO

ISIN

CA4990531069

WKN

A1XE7A

In 2024, Knight Therapeutics's market cap stood at 566.35 M CAD, a 1.46% increase from the 558.18 M CAD market cap in the previous year.

The Knight Therapeutics Market capitalization history

YEARMarket Capitalization (undefined CAD)
20230.52
20220.62
20210.66
20200.87
20191.07
20181.16
20171.36
20161.02
20150.74
20140.33

Knight Therapeutics Aktienanalyse

What does Knight Therapeutics do?

Knight Therapeutics Inc is a Canadian biopharmaceutical company that was founded in 2014. The company is listed on the Toronto Stock Exchange and NASDAQ, making it accessible to all investors. The company's business philosophy is based on the "Acquire and Develop" model, which involves developing acquired products or products that were previously in the approval phase for market testing. Knight Therapeutics focuses on the development and commercialization of pharmaceutical products in Latin America and Canada. The company has gained overseas experience by signing long-term agreements with significant international pharmaceutical companies, including a Japanese and a South Korean pharmaceutical company. In Canada, Knight is in a position to meet the increased demand for innovative drug research and provide patients with important therapies. In Latin America, they focus on achieving broader access to innovative drugs. In this regard, the company is actively working to expand its portfolio of safe, high-quality, and effective medications for this region. The company's product range includes a wide range of priority pharmaceutical areas such as cancer treatments, eye diseases, cardiology, infectious diseases, and pain relief. The company has the expertise to manufacture and distribute specialized treatment options for many diseases, such as cancer and rare diseases. One of Knight Therapeutics' most well-known products is the drug Probuphine. It was approved by the US Food and Drug Administration in May 2016 to help patients with opioid dependence. Knight acquired the product under license from the manufacturer Braeburn Pharmaceuticals. Permian LLC, a real estate fund specializing in retail properties, attempted to acquire Knight with a $150 per share offer. However, this deal was rejected due to Knight's stock dilutions. Another important product of the company is Neuragen, which is used for neuropathic pain and fibromyalgia. It is currently approved in Canada and Brazil, but approvals in the US and other countries are also being sought. Furthermore, Knight Therapeutics is also involved in the manufacturing of generic narcotics and has already concluded some potentially profitable contracts to introduce these products into the Latin American pharmaceutical market. The company has also signed an extremely promising agreement with SAI Life Sciences to develop compounds for the treatment of pain and inflammation. Knight Therapeutics' roadmap also includes a strong partnership with Canadian company Triumvira Immunologics for the further development of cancer treatments, as well as a collaboration with Endoceutics to introduce Prasterone, a superior treatment for vaginal atrophy, menopausal symptoms, and hot flashes in women, to increase bone density and improve sexual life. Overall, Knight Therapeutics has a solid reputation as an emerging player in the pharmaceutical market and is known for its advanced research and development of drugs, with a particular focus on oncology, ophthalmology, and cardiology. It remains to be seen how the company will develop in the future, but it appears that with the aggressive development of innovative products and the expansion into new markets, Knight has great potential to increase its market share in the pharmaceutical industry as a whole. Knight Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Knight Therapeutics's Market Capitalization

Knight Therapeutics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Knight Therapeutics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Knight Therapeutics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Knight Therapeutics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Knight Therapeutics stock

What is the current Knight Therapeutics market capitalization?

The current market capitalization of Knight Therapeutics is 566.35 M CAD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Knight Therapeutics.

How has the market capitalization of Knight Therapeutics developed in recent years?

The market capitalization of Knight Therapeutics has increased/decreased by 1.46% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Knight Therapeutics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Knight Therapeutics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Knight Therapeutics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Knight Therapeutics pay?

Over the past 12 months, Knight Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Knight Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Knight Therapeutics?

The current dividend yield of Knight Therapeutics is .

When does Knight Therapeutics pay dividends?

Knight Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Knight Therapeutics?

Knight Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Knight Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Knight Therapeutics located?

Knight Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Knight Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Knight Therapeutics from 12/2/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 12/2/2024.

When did Knight Therapeutics pay the last dividend?

The last dividend was paid out on 12/2/2024.

What was the dividend of Knight Therapeutics in the year 2023?

In the year 2023, Knight Therapeutics distributed 0 CAD as dividends.

In which currency does Knight Therapeutics pay out the dividend?

The dividends of Knight Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Knight Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Knight Therapeutics

Our stock analysis for Knight Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Knight Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.